Justin J. McAnear - 19 Mar 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Financial Officer
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Issuer symbol
TXG
Transactions as of
19 Mar 2021
Net transactions value
-$45,707
Form type
4
Filing time
26 May 2021, 20:26:47 UTC
Next filing
03 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Award $0 +8,935 +29% $0.000000 39,292 19 Mar 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale $45,707 -281 -0.72% $162.66 39,011 24 May 2021 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Award $0 +22,338 $0.000000 22,338 19 Mar 2021 Class A Common Stock 22,338 $177.76 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock. One-sixteenth of the RSUs shall vest on May 21, 2021 and on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2 The number of shares beneficially owned following the reported transaction is as of March 19, 2021.
F3 These shares were sold to cover tax withholding obligations in connection with the vesting of RSUs.
F4 The number of shares beneficially owned following the reported transaction is as of May 24, 2021.
F5 This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2021 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.